
    
      The primary objective for this study is to compare headache relief (defined as a reduction
      from moderate [Grade 2] or severe [Grade 3] pain to none [Grade 0] or mild [Grade 1] pain) at
      120 minutes following a dose of 20 mg of OPTINOSE SUMATRIPTAN with placebo in the acute
      treatment of a single migraine attack.
    
  